<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429936</url>
  </required_header>
  <id_info>
    <org_study_id>SRFR-001</org_study_id>
    <nct_id>NCT00429936</nct_id>
  </id_info>
  <brief_title>Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration</brief_title>
  <official_title>A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ReVision Therapeutics, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sirion Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase II study is to determine the efficacy of fenretinide in the
      treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular
      degeneration (AMD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GA lesion progression</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Geographic Atrophy</condition>
  <condition>Dry Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>100 mg fenretinide softgel capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three (3) 100-mg fenretinide softgel capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenretinide and placebo softgel capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One (1) 100-mg fenretinide softgel capsule and two (2) placebo softgel capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo softgel capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three (3) placebo softgel capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenretinide</intervention_name>
    <description>Once daily 30 minutes after the evening meal for 24 months</description>
    <arm_group_label>100 mg fenretinide softgel capsules</arm_group_label>
    <arm_group_label>Fenretinide and placebo softgel capsules</arm_group_label>
    <arm_group_label>Placebo softgel capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males or females, 50 to 89 years of age

          -  must have GA from AMD in one or both eyes

        Exclusion Criteria:

          -  GA due to any disease other than AMD (eg, drug-induced)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Vogel, MD</last_name>
    <role>Study Director</role>
    <affiliation>ReVision Therapeutics Advisor</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2007</study_first_submitted>
  <study_first_submitted_qc>January 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <last_update_submitted>June 21, 2010</last_update_submitted>
  <last_update_submitted_qc>June 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>ReVision Therapeutics, Inc.</name_title>
    <organization>ReVision Therapeutics, Inc.</organization>
  </responsible_party>
  <keyword>Dry Age Related Macular Degeneration</keyword>
  <keyword>Geographic Atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

